3D Medicines, Inc. (HK:1244) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
3D Medicines Inc., in their supplemental announcement, detailed the allocation and usage of proceeds from their Global Offering after their December 2022 listing on The Stock Exchange of Hong Kong Limited. A significant majority of the proceeds, 90%, is dedicated to research, development, and commercialization of their products, including envafolimab and other drug candidates, with a timeline extending to December 2025. The remaining funds are allocated to general corporate and working capital purposes.
For further insights into HK:1244 stock, check out TipRanks’ Stock Analysis page.